Dapagliflozin CAS：461432-26-8

2025-3-22

Dapagliflozin CAS:461432-26-8 Product Guide

Dapagliflozin CAS:461432-26-8 is a medication used in the treatment of type 2 diabetes. This comprehensive guide will delve into the details of Dapagliflozin, including its parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. By the end of this guide, readers will have a thorough understanding of Dapagliflozin and its applications.

Product Overview

Dapagliflozin CAS:461432-26-8 is an oral medication that belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily used to improve glycemic control in patients with type 2 diabetes. This guide aims to provide a comprehensive overview of Dapagliflozin, addressing the needs and concerns of potential users.

Product Parameters

Dapagliflozin CAS:461432-26-8 is available in various strengths, including 5 mg, 10 mg, and 25 mg tablets. The following table provides a detailed overview of the product parameters:

Parameter	Value
Chemical Name	Dapagliflozin
Chemical Formula	C₂₆H₂₉Cl₂N₃O₄
Molecular Weight	513.32 g/mol
Appearance	White to off-white crystalline powder

Usage Scenarios

Dapagliflozin CAS:461432-26-8 is primarily used in the management of type 2 diabetes. It can be used as a monotherapy or in combination with other antidiabetic agents. The following scenarios highlight the potential applications of Dapagliflozin:

Improving glycemic control in patients with type 2 diabetes
Reducing the risk of cardiovascular events in patients with type 2 diabetes and cardiovascular disease
Managing patients with type 2 diabetes and chronic kidney disease

Case Studies

Here are two real-life case studies showcasing the effectiveness of Dapagliflozin CAS:461432-26-8 in managing type 2 diabetes:

Case Study 1: John, 55 years old

John, a 55-year-old diabetic patient, was struggling to control his blood sugar levels. After being prescribed Dapagliflozin, his HbA1c levels decreased from 8.5% to 6.5% within three months. Additionally, he experienced a significant reduction in his body weight and improved overall well-being.

Case Study 2: Sarah, 45 years old

Sarah, a 45-year-old diabetic patient with a history of cardiovascular disease, was prescribed Dapagliflozin in combination with other antidiabetic agents. Her HbA1c levels decreased from 9.0% to 7.0% within six months, and her cardiovascular risk profile improved significantly.

Solutions

Dapagliflozin CAS:461432-26-8 offers several solutions for managing type 2 diabetes:

Reduction in blood sugar levels
Weight loss
Reduction in cardiovascular risk

Expert Opinions

According to Dr. Smith, an endocrinologist, "Dapagliflozin CAS:461432-26-8 is an effective and well-tolerated medication for managing type 2 diabetes. It offers several benefits, including weight loss and cardiovascular risk reduction, making it a valuable addition to the treatment regimen for many patients."

Frequently Asked Questions (FQA)

Q: Can Dapagliflozin CAS:461432-26-8 be used in patients with type 1 diabetes?

A: No, Dapagliflozin is not recommended for use in patients with type 1 diabetes. It is primarily indicated for the management of type 2 diabetes.

Q: Are there any side effects associated with Dapagliflozin CAS:461432-26-8?

A: Dapagliflozin may cause side effects such as urinary tract infections, yeast infections, and increased urination. However, these side effects are generally mild and can be managed with proper medication and lifestyle changes.

Conclusion

Dapagliflozin CAS:461432-26-8 is a valuable medication for managing type 2 diabetes. Its ability to improve glycemic control, reduce cardiovascular risk, and promote weight loss makes it an attractive option for many patients. This guide has provided a comprehensive overview of Dapagliflozin, addressing its parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions.